Imagine a world where vital organs could be kept alive and healthy outside the body for extended periods, revolutionizing transplant medicine and life support. This is the ambitious goal of Science Corporation, a company founded by former Neuralink president Max Hodak. But how exactly are they planning to achieve this? Let's dive in.
Science Corporation, established in 2021, is venturing into the fascinating realm of organ preservation, a field distinct from its initial focus on brain-computer interfaces. Their primary objective? To enhance the capabilities of current perfusion systems. These systems are designed to circulate blood through vital organs when they can't function independently, extending their lifespan.
Currently, these systems, crucial for preserving organs for transplants and supporting patients when their heart and lungs fail, are often cumbersome and expensive. Science aims to develop a smaller, more portable, and more cost-effective solution, enabling long-term organ support. But here's where it gets controversial: Could this technology potentially extend human lifespans in ways we haven't even imagined?
Before this shift, Science concentrated on neural interfaces and vision restoration. They're developing a "biohybrid" interface that uses living neurons to connect to the brain. They're also close to commercializing their retinal implant, which has successfully restored some vision in patients with advanced macular degeneration. This implant, acquired from the French startup Pixium Vision, has positioned Science ahead of Elon Musk's Neuralink in the race to combat vision loss. This raises a key question: Are these technologies, including organ preservation, ultimately about extending human longevity?
Max Hodak, who co-founded Neuralink with Elon Musk in 2016 but left in 2021 to lead Science, drew inspiration from a poignant case involving a 17-year-old boy with cystic fibrosis. The boy's lungs failed, and he was sustained by extracorporeal membrane oxygenation (ECMO) while awaiting a transplant. However, complications arose, making him ineligible for the transplant, and the boy eventually passed away. This highlights the ethical dilemmas and limitations of current life-support systems.
ECMO machines, used extensively during the COVID-19 pandemic, are expensive, costing thousands of dollars daily. Patients are confined to hospitals, tethered to these large, complex systems that require constant monitoring and manual adjustments. Because of their high cost, not every hospital has them. Could Science's innovations offer a more accessible solution?
Beyond ECMO, perfusion systems for organ transplants are also costly. For instance, TransMedics, based in Massachusetts, offers an organ care system costing around $250,000 for the machine, plus $40,000 to $80,000 per use. Organs often travel via private jets, underscoring the expense and complexity of current methods.
Science's team has already made significant strides, keeping rabbit kidneys alive outside the body for up to 48 hours. They aim to extend this to a month by next spring. A human kidney can remain viable for 24 to 36 hours on ice, while existing perfusion machines can extend this to four days or longer. This could dramatically increase the availability of transplant organs.
Branching into organ perfusion was always part of Hodak's plan for Science, which now employs around 170 people. Their prototype includes integrated sensors for real-time monitoring of blood oxygenation, flow rate, pressure, and temperature. It also features a modular design with swappable components and closed-loop control for automatic adjustments, unlike manual ECMO machines.
Science will be competing with other companies in the automated perfusion systems market. Hodak aims to provide a more affordable alternative, bridging the gap between what this technology can do and how it is currently used. If successful, this could transform medicine, potentially leading to a world of "swappable parts."
What are your thoughts on this technology? Do you think it will revolutionize medicine, or are there ethical concerns that need to be addressed? Share your opinions in the comments below!
